BRNS
NASDAQBarinthus Biotherapeutics plc
Price$0.68+0.10 (+16.54%)
2026-03-032026-06-04
News · 26 weeks16-83%
2025-12-072026-05-31
Mix1190d
- SEC Filings8(73%)
- Earnings2(18%)
- Insider1(9%)
Latest news
25 items- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- INSIDERSEC Form 3 filed by new insider Swirsky Douglas J3 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- SECSEC Form 10-Q filed by Barinthus Biotherapeutics plc10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsProposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closingMultiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company's corporate deve
- SECSEC Form DEFM14A filed by Barinthus Biotherapeutics plcDEFM14A - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form 10-K filed by Barinthus Biotherapeutics plc10-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate DevelopmentsProposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company's base of high caliber institutional investors, expected to complete in the second quarter of 2026Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company's co
- SECSEC Form 425 filed by Barinthus Biotherapeutics plc425 - Barinthus Biotherapeutics plc. (0001828185) (Subject)
- SECSEC Form 8-K filed by Barinthus Biotherapeutics plc8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseVTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEs The MAD portion of the trial, which includes a gluten challenge, is ongoing GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing immune tolerance therapies with curative potential, today announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. In the single ascending dose ("SAD") portion of the trial
- SECSEC Form 10-Q filed by Barinthus Biotherapeutics plc10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate DevelopmentsSingle ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") to strengthen and diversify the pipeline and broaden the Company's base of high caliber institutional investors. GERMANTOWN, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended
- PRChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus TherapeuticsSAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ:BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.
- SECSEC Form 425 filed by Barinthus Biotherapeutics plc425 - Barinthus Biotherapeutics plc. (0001828185) (Subject)
- SECSEC Form 425 filed by Barinthus Biotherapeutics plc425 - Barinthus Biotherapeutics plc. (0001828185) (Subject)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Regulation FD Disclosure8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune DiseasesThe combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company extends through 2027.Transaction projected to close in the first half of 2026. The combined company will be backed by OrbiMed and Torrey Pines and is expected to trade under the NASDAQ symbol "CLYD." GERMANTOWN, Md. and ALTRINCHAM, United Kingdom, Sept. 30, 2025 (GLOBE NE
- SECAmendment: Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K/A - Barinthus Biotherapeutics plc. (0001828185) (Filer)
BRNS FAQ
5 questionsWhere does BRNS stock trade?
Barinthus Biotherapeutics plc (BRNS) is listed on NASDAQ.What sector and industry is BRNS in?
Barinthus Biotherapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Barinthus Biotherapeutics plc go public?
Barinthus Biotherapeutics plc (BRNS) completed its IPO in 2021.What companies are similar to BRNS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BRNS side-by-side with any of them on Quantisnow.How can I track BRNS on Quantisnow?
Quantisnow aggregates Barinthus Biotherapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRNS to receive live email and push alerts on every new disclosure.